From the Streetlab (C.N.A., M.P., A.T., A.D., A.Z., C.C.), Paris, France.
From the Streetlab (C.N.A., M.P., A.T., A.D., A.Z., C.C.), Paris, France.
Am J Ophthalmol. 2024 Feb;258:43-54. doi: 10.1016/j.ajo.2023.06.028. Epub 2023 Jul 16.
To validate a novel mobility test (MOST, MObility Standardized Test) and performance outcomes in real (RL) and virtual (VR) environments to be used for interventional clinical studies in order to characterize vision impairment in rod-cone dystrophies, also known as retinitis pigmentosa (RP).
Prospective, interventional, noninvasive, reliability and validity analysis.
We designed MOST to be used in both VR and RL and conducted 3 experimental studies with 89 participants to (1) validate the difficulty of the mobility courses (15 controls), (2) determine the optimal number of light levels and training trials (14 participants with RP), and (3) validate the reproducibility (test-retest), reliability (VR/RL), sensitivity, and construct/content validity of the test (30 participants with RP and 30 controls). A comprehensive ophthalmologic examination was performed in all subjects. Outcomes of interest included MOST performance score, visual acuity, contrast sensitivity, dark adaptation thresholds, visual field parameters, and correlation between the performance score and visual function.
The mobility courses exhibited statistically similar difficulty, and 5 trials are sufficient to control for the learning effect. MOST is highly reproducible (test-retest correlations >0.98) and reliable (correlations VR/RL = 0.98). MOST achieved a discrimination between participants with RP and controls (accuracy >95%) and between early and late stages of the disease (82.3% accuracy). The performance score is correlated with visual function parameter (0.57-0.94).
MOST is a validated mobility test, with the controlled learning effect, excellent reproducibility, and high agreement between RL and VR conditions, as well as sensitivity and specificity to measure disease progression and therapeutic benefit in rod-cone dystrophies.
验证一种新的移动测试（MOST，移动标准化测试）和在真实（RL）和虚拟（VR）环境中的表现结果，以便在干预性临床研究中用于描述视杆-视锥营养不良（也称为色素性视网膜炎（RP））患者的视力障碍。
前瞻性、干预性、非侵入性、可靠性和有效性分析。
我们设计了 MOST 以便在 VR 和 RL 中使用，并进行了 3 项实验研究，共有 89 名参与者参与：（1）验证移动课程的难度（15 名对照者），（2）确定最佳的光水平和训练试验数量（14 名 RP 患者），以及（3）验证测试的重现性（测试-重测）、可靠性（VR/RL）、敏感性和结构/内容有效性（30 名 RP 患者和 30 名对照者）。所有受试者均进行了全面的眼科检查。感兴趣的结果包括 MOST 表现得分、视力、对比敏感度、暗适应阈值、视野参数以及表现得分与视觉功能之间的相关性。
移动课程表现出统计学上相似的难度，并且 5 次试验足以控制学习效果。MOST 具有高度的重现性（测试-重测相关性>0.98）和可靠性（VR/RL 相关性=0.98）。MOST 能够区分 RP 患者和对照组（准确率>95%）以及疾病的早期和晚期（准确率 82.3%）。表现得分与视觉功能参数相关（0.57-0.94）。
MOST 是一种经过验证的移动测试，具有可控制的学习效果、出色的重现性以及 RL 和 VR 条件之间的高度一致性，以及对测量杆-锥营养不良疾病进展和治疗效果的敏感性和特异性。
